John Cannella, MD
Gastroenterology · Omaha, NENPI 1619099629
Payments from drug & device makers
What this record shows
Almost everything reported here is food and beverage — 99.3% of the total across 217 separate payments, which is the pattern of a clinician who attends manufacturer presentations rather than one with a consulting arrangement. It is spread thinly across 24 manufacturers, the largest accounting for just 18.6% — the pattern of someone who eats at a lot of different presentations. 2025 is the largest year on record at $887, 2.2 times the $412 reported in 2019.
Across 217 payments — averaging $18.42 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- AbbVie$744
- QOL Medical, LLC$519
- Takeda Pharmaceuticals U.S.A., Inc.$430
- Gilead$396
- Johnson & Johnson$311
- Sanofi$237
- plus $1K from 18 others
What the payments were for
- Food & beverage$3,96999%
- Other$301%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| AbbVie(2 entities) | 49 | $744 |
| QOL Medical, LLC | 33 | $519 |
| Takeda Pharmaceuticals U.S.A., Inc. | 24 | $430 |
| Gilead | 18 | $396 |
| Johnson & Johnson | 17 | $311 |
| Sanofi | 10 | $237 |
| Salix Pharmaceuticals, A Division Of Bausch Health US, LLC | 12 | $216 |
| Aimmune Therapeutics, Inc. | 1 | $178 |
| Daiichi Sankyo Inc. | 2 | $133 |
| Ironwood Pharmaceuticals, Inc | 7 | $112 |
| Madrigal Pharmaceuticals | 5 | $99 |
| Amgen | 5 | $94 |
| Regeneron Healthcare Solutions, Inc. | 4 | $91 |
| Bristol Myers Squibb | 5 | $87 |
| Pfizer | 4 | $71 |
| Intercept Pharmaceuticals, Inc. | 4 | $64 |
| Merck | 3 | $52 |
| Phathom Pharmaceuticals, Inc. | 6 | $47 |
| Ardelyx, Inc. | 2 | $34 |
| Ferring Pharmaceuticals Inc. | 2 | $27 |
| Welch Allyn | 1 | $17 |
| Celltrion USA Inc. | 1 | $17 |
| Baxter Healthcare | 1 | $13 |
| UCB, Inc. | 1 | $11 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
How this compares
$3,998 in reported general payments places this provider in the 60th percentile of 89 gastroenterology providers in Nebraska.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| StelaraUstekinumab | 35 | $913,394 |
| OcalivaObeticholic Acid | 12 | $110,955 |
| RinvoqUpadacitinib | 14 | $104,651 |
| XifaxanRifaximin | 11 | $31,400 |
| LinzessLinaclotide | 29 | $21,471 |
| Mesalamine | 41 | $15,925 |
| Ursodiol | 45 | $6,299 |
| Peg 3350-ElectrolyteSodium Chloride/Nahco3/Kcl/Peg | 308 | $6,238 |
| Mercaptopurine | 53 | $5,794 |
| TrulancePlecanatide | 11 | $5,569 |
| Pantoprazole Sodium | 233 | $2,551 |
| Budesonide DrBudesonide | 14 | $2,510 |
| Colestipol Hcl | 35 | $2,155 |
| Sucralfate | 31 | $1,890 |
| Mesalamine ErMesalamine | 18 | $1,814 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Johnson & JohnsonStelara | $311 | $913,39435 claims |
| AbbVieRinvoq, Linzess | $744 | $126,12243 claims |
| Intercept Pharmaceuticals, Inc.Ocaliva | $64 | $110,95512 claims |
| Salix Pharmaceuticals, A Division Of Bausch Health US, LLCXifaxan, Trulance | $216 | $36,96922 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 60th percentile of 89 gastroenterology providers in Nebraska.
Other gastroenterology in Omaha
- Benjamin HallOmaha$154K
- Sandeep MukherjeeOmaha$145K
- Rowen ZettermanOmaha$119K
- Derrick EicheleOmaha$54K
- Joshua EvansOmaha$34K
- Michael SchaferOmaha$30K
- Peter MannonOmaha$30K
- Helen Fasanya-UptagraftOmaha$26K
- Rajani RangrayOmaha$15K
- Grant HutchinsOmaha$15K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.